Frontlight ResearchEarly access
TerminatedPhase 4
MicroRNA Activation of LOX-1 Mechanisms in Endometriosis
Key facts
- Who runs it
- Penn State University
- Where
- University Park, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 4
- People taking part
- 6 people enrolled
- Started
- 1 May 2018
- Ended
- 31 Aug 2024
- Type of study
- Interventional
- Treatments tested
- Atorvastatin
- Record updated
- 30 January 2025
- Why it stopped
- COVID halting human subjects research and preliminary data from this proposal were used to submit an NIH grant. The NIH grant was funded and 3 other protocols were launched.
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Women between the ages of 18 and 45 years with endometriosis (diagnosis by prior laparoscopy by subject's own physician <5 years prior, and reported by the subject to the researchers)
Who cannot take part
- Taking pharmacotherapy that could alter peripheral vascular control (e.g. insulin sensitizing, cardiovascular medications)
- Taking illicit and/or recreational drugs
- Rash, skin disease, disorders of pigmentation, known skin allergies
- Diagnosed or suspected metabolic or cardiovascular disease
- Known allergy to latex or investigative substances
- Diabetes (HbA1C .6.5%)
- Persistent unexplained elevations of serum transaminases
- Use of nicotine-containing products (e.g. smoking, chewing tobacco, etc.)
- BP>140/90
- Pregnancy
- Breastfeeding
- Abnormal liver function
Where in United States
- The Pennsylvania State UniversityUniversity Park, United States
About the trial
What the trial wants to find out
Endometriosis is a disorder that occurs in women. With endometriosis, tissue that should be found in the womb is found in sites outside of the womb. This disorder impairs the function of the cells that line the body's blood vessels (endothelium). The endothelium helps to control blood flow in healthy vessels. Women with this disorder have an increased risk for high blood pressure and high cholesterol. They have a higher risk for cardiovascular disease, too. With this study, we will learn how endometriosis impairs the lining of blood vessels and increases the risk for disease.
The group in the trial
- AtorvastatinTreatment being tested
Oral atorvastatin (Lipitor) therapy (10mg/day) for seven days. Atorvastatin acts as a systemic LOX inhibitor.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 30 January 2025